Roles of LncRNA-MALAT1 in the Progression and Prognosis of Gliomas

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2023 Oct 20

PMID 37859309

Authors

Yu-Long Ji

Kai Kang

Qiao-Li Lv

Da-Peng Wang

Affiliations

Soon will be listed here.

Abstract

Long noncoding RNAs (lncRNAs) represent a large subgroup of RNA transcripts that lack the function of coding proteins and may be essential universal genes involved in carcinogenesis and metastasis. LncRNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNAMALAT1) is overexpressed in various human tumors, including gliomas. However, the biological function and molecular mechanism of action of lncRNA-MALAT1 in gliomas have not yet been systematically elucidated. Accumulating evidence suggests that the abnormal expression of lncRNA-MALAT1 in gliomas is associated with various physical properties of the glioma, such as tumor growth, metastasis, apoptosis, drug resistance, and prognosis. Furthermore, lncRNAs, as tumor progression and prognostic markers in gliomas, may affect tumorigenesis, proliferation of glioma stem cells, and drug resistance. In this review, we summarize the knowledge on the biological functions and prognostic value of lncRNA-MALAT1 in gliomas. This mini-review aims to deepen the understanding of lncRNA-MALAT1 as a novel potential therapeutic target for the individualized precision treatment of gliomas.

Citing Articles

Long noncoding RNA SNHG4 promotes glioma progression via regulating miR-367-3p/MYO1B axis in zebrafish xenografts.

Zhang Y, Wang Y, Yang Y, Sun C Hum Cell. 2025; 38(2):53.

PMID: 39951205 PMC: 11828807. DOI: 10.1007/s13577-025-01183-1.

The emerging roles of aberrant alternative splicing in glioma.

Ben Mrid R, El Guendouzi S, Mineo M, El Fatimy R Cell Death Discov. 2025; 11(1):50.

PMID: 39915450 PMC: 11802826. DOI: 10.1038/s41420-025-02323-0.

The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

Bora Yildiz C, Du J, Mohan K, Zimmer-Bensch G, Abdolahi S Epigenomics. 2025; 17(2):125-140.

PMID: 39829063 PMC: 11792803. DOI: 10.1080/17501911.2024.2442297.

References

Waker C, Lober R . Brain Tumors of Glial Origin. Adv Exp Med Biol. 2019; 1190:281-297. DOI: 10.1007/978-981-32-9636-7_18. View

Wang D, Kang K, Lin Q, Hai J . Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta-Analysis. Clin Transl Sci. 2019; 13(1):179-188. PMC: 6951460. DOI: 10.1111/cts.12700. View

Gritsch S, Batchelor T, Gonzalez Castro L . Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2021; 128(1):47-58. DOI: 10.1002/cncr.33918. View

Lah T, Novak M, Breznik B . Brain malignancies: Glioblastoma and brain metastases. Semin Cancer Biol. 2019; 60:262-273. DOI: 10.1016/j.semcancer.2019.10.010. View

Brandner S, Jaunmuktane Z . Neurological update: gliomas and other primary brain tumours in adults. J Neurol. 2017; 265(3):717-727. PMC: 5834564. DOI: 10.1007/s00415-017-8652-3. View

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

Gatto L, Di Nunno V, Franceschi E, Tosoni A, Bartolini S, Brandes A . Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. Drugs. 2022; 82(5):491-510. DOI: 10.1007/s40265-022-01702-6. View

Kirby A, Finnerty G . New strategies for managing adult gliomas. J Neurol. 2020; 268(10):3666-3674. PMC: 8463358. DOI: 10.1007/s00415-020-09884-3. View

Beermann J, Piccoli M, Viereck J, Thum T . Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016; 96(4):1297-325. DOI: 10.1152/physrev.00041.2015. View

10.

Hombach S, Kretz M . Non-coding RNAs: Classification, Biology and Functioning. Adv Exp Med Biol. 2016; 937:3-17. DOI: 10.1007/978-3-319-42059-2_1. View

11.

Gil N, Ulitsky I . Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2019; 21(2):102-117. DOI: 10.1038/s41576-019-0184-5. View

12.

Zhang X, Hamblin M, Yin K . The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017; 14(12):1705-1714. PMC: 5731810. DOI: 10.1080/15476286.2017.1358347. View

13.

Ghafouri-Fard S, Ashrafi Hafez A, Taheri M . Metastasis Associated Lung Adenocarcinoma Transcript 1: An update on expression pattern and functions in carcinogenesis. Exp Mol Pathol. 2019; 112:104330. DOI: 10.1016/j.yexmp.2019.104330. View

14.

Han Y, Wu Z, Wu T, Huang Y, Cheng Z, Li X . Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016; 7:e2123. PMC: 4823926. DOI: 10.1038/cddis.2015.407. View

15.

Liao K, Lin Y, Gao W, Xiao Z, Medina R, Dmitriev P . Blocking lncRNA MALAT1/miR-199a/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression. Mol Ther Nucleic Acids. 2019; 18:388-399. PMC: 6819876. DOI: 10.1016/j.omtn.2019.09.005. View

16.

Baspinar Y, Elmaci I, Ozpinar A, Altinoz M . Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles' heal?. Gene. 2020; 739:144518. DOI: 10.1016/j.gene.2020.144518. View

17.

Wang L, Li S, Stone S, Liu N, Gong K, Ren C . The Role of the lncRNA MALAT1 in Neuroprotection against Hypoxic/Ischemic Injury. Biomolecules. 2022; 12(1). PMC: 8773505. DOI: 10.3390/biom12010146. View

18.

Lei L, Chen J, Huang J, Lu J, Pei S, Ding S . Functions and regulatory mechanisms of metastasis-associated lung adenocarcinoma transcript 1. J Cell Physiol. 2018; 234(1):134-151. DOI: 10.1002/jcp.26759. View

19.

Li C, Chen Y . Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013; 45(8):1895-910. DOI: 10.1016/j.biocel.2013.05.030. View

20.

Sun Y, Ma L . New Insights into Long Non-Coding RNA in Cancer and Metastasis. Cancers (Basel). 2019; 11(2). PMC: 6406606. DOI: 10.3390/cancers11020216. View